Genomic Portraits: Reflections into a Tumor's Response to Therapy
SF Slovin - Clinical Cancer Research, 2023 - AACR
Well-annotated matched tissue specimens both before and after initiation of androgen
receptor signaling inhibitors (ARSI) have revealed activation of unique signaling pathways …
receptor signaling inhibitors (ARSI) have revealed activation of unique signaling pathways …
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein, P Lal, E LaTulippe, A Smith… - The American journal of …, 2004 - Elsevier
The androgen-signaling pathway is critical to the development and progression of prostate
cancer and androgen ablation is a mainstay of therapy for this disease. We performed a …
cancer and androgen ablation is a mainstay of therapy for this disease. We performed a …
A genomic strategy for predicting androgen receptor activity in prostate tumors
JG Jonsson, T Sissung, WD Figg - cancer Biology & therapy, 2009 - Taylor & Francis
Mendiratta et al. have developed an AR signature for prostate cancer that is based on the
expression of 300 genes. The AR signature is decreased with androgen deprivation therapy …
expression of 300 genes. The AR signature is decreased with androgen deprivation therapy …
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer
PS Nelson - Journal of clinical oncology, 2012 - ascopubs.org
“You can observe a lot just by watching.”—Yogi Berra The androgen receptor (AR) is a
resilient foe. Since the landmark studies of Huggins et al1 demonstrated the sensitivity of …
resilient foe. Since the landmark studies of Huggins et al1 demonstrated the sensitivity of …
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for
men with castration-resistant prostate cancer (CRPC). However, not all patients respond …
men with castration-resistant prostate cancer (CRPC). However, not all patients respond …
Abstract P6-07-08: Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling
A Gucalp, TA Proverbs-Singh, P Razavi… - Cancer Research, 2016 - AACR
Background: AR mutations have been described as a mechanism of resistance to AR
antagonists in prostate cancer. There are limited data regarding the presence of AR …
antagonists in prostate cancer. There are limited data regarding the presence of AR …
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Purpose: The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized
in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the …
in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the …
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer
Background Genomic alterations to the androgen receptor (AR) are common in metastatic
castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand …
castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand …
Genomic strategy for targeting therapy in castration-resistant prostate cancer
Purpose Despite treatments which lower circulating androgens, advanced prostate cancers
often maintain androgen receptor (AR) signaling. The variable response to secondary …
often maintain androgen receptor (AR) signaling. The variable response to secondary …
Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies
N Mitsiades, N Schultz, BS Taylor… - Journal of Clinical …, 2009 - ascopubs.org
5002 Background: Androgen receptor (AR) signaling remains active in castration-resistant
prostate cancer (CRPC) despite castrate levels of circulating androgens. This is indicated by …
prostate cancer (CRPC) despite castrate levels of circulating androgens. This is indicated by …